of antinuclear antibodies<0.001), combination therapy of methotrexate with other conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) (p=0.001), a shorter period of first medical treatment (p = 0.012) and high erythrocyte sedimentation rate (ESR) (p = 0.027). In multivariate analysis, three factors were independently related to the need of joint surgery: age at disease onset (OR 2.799 95%CI: 1.49-5.22 p<0.01), high ESR level (OR 2.807 95%CI: 1.5-5.24 p=0.01), and association of Methotrexate with other csDMARDs (OR 3.500 95%CI: 1.61-7.56 p<0.01).

Conclusion: Twelve percent of RA patients needed joint surgery treatment. Predictive factors of surgical treatment were young age at disease onset, high ESR level and association of methotrexate with other csDMARDs.

REFERENCES

Disclosure of Interests: None declared

AB0445 REMARKABLE OUTCOMES IN PATIENTS WITH RA USING CONVENTIONAL DMARDS UNDER A T2T STRATEGY AND A DISEASE MANAGEMENT MODEL – RESULTS FROM A FIVE YEAR REAL-WORLD REGISTRY

Pedro Santos-Moreno1, Michael Cabrera2, Diana Buitrago-Garcia3, Eva Cardozo1, Ivana Ramirez1, Danny Gomez1, Edwin Castillo2, Sandra Farietta1,2; Biobam – Center for rheumatoid arthritis, Rheumatology, Bogotá, Colombia; 2Biobam – Center for rheumatoid arthritis, EHR administration, Bogotá, Colombia; 3Biobam – Center for rheumatoid arthritis, Nursing research, Bogotá, Colombia

Background: Rheumatoid arthritis (RA) is a common chronic inflammatory disease. Treat-to-target (T2T) is a management strategy for RA that proposes as the therapeutic target a state of remission or low disease activity, additionally a multidisciplinary management of patients with RA has demonstrated to be an additional aid to achieve remission or low disease activity. Real-world evidence (RWE) refers to information coming from electronic health records, billing data, registries among others. RWE shows results that are difficult for clinical trials to demonstrate due to ideal conditions(1, 2).

Objectives: The aim of this study was to describe global change in Disease Activity Score 28 (DAS28) using T2T strategy during 5 years in a cohort of patients receiving conventional DMARDs that attend to a specialized RA center.

Methods: A descriptive cohort study was conducted. Medical records of patients from specialized in RA center were reviewed during 2015-2017; those patients were followed-up under T2T standards and a multidisciplinary approach. Clinical follow-up was designed by the authors according to DAS28 as follows: every 3-5 weeks (DAS28 > 5.1), every 7-9 weeks (DAS28 ≥ 3.1 and ≤ 5.1), and every 11-13 weeks (DAS28 < 3.1). Tender joint count (TJC), swollen joint count (SJC) and DAS28 were measured on each visit. Therapy had to be adjusted with DAS28 > 3.2 unless patient’s conditions don’t permit it; we considered this follow-up type as implementation of a T2T strategy in patients with RA. Patients entered into a multidisciplinary program of care with periodic consultations, except patient’s conditions don’t permit it. We included 2,128 patients. 83% were female and 17% were male, mean age was 57 years ±14. At baseline median DAS28 4.34 RIQ (3.76-5.06) and at 5 years 2.02 RIQ (1.46-2.38). At the end of our follow-up 81% were remission and 7% in LDA. See table 1.

<table>
<thead>
<tr>
<th>ACTIVITY LEVEL</th>
<th>BASELINE</th>
<th>3 YEARS FOLLOW-UP</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (% )</td>
<td>n (% )</td>
</tr>
<tr>
<td>LDA</td>
<td>5</td>
<td>1726</td>
</tr>
<tr>
<td>MDA</td>
<td>1628</td>
<td>147</td>
</tr>
<tr>
<td>SDA</td>
<td>495</td>
<td>23.39</td>
</tr>
</tbody>
</table>

Conclusion: In our patients T2T improves associated with a disease management model, improves disease activity in patients with RA. This evidence comes from a real-life setting that shows the advantages of treating RA patients with a multidisciplinary team under a T2T model with a low-cost treatment. It is important to explore other predictors that can improve disease activity.

Disclosure of Interests: Pedro Santos-Moreno Grant/research support from: Dr Santos has received research grants from Janssen, Abbvie and UCB, Speakers bureau: Dr Santos has received speaker fees from Sanofi, Lilly, Bristol, Pfizer, Abbvie, Janssen and UCB, Michael Cabrera: None declared, Diana Buitrago-Garcia: None declared, Eva Cardozo: None declared, Ivana Ramirez: None declared, Danny Gomez: None declared, Edwin Castillo: None declared, Sandra Farietta: None declared

AB0446 REAL-LIFE USE OF BARICITINIB IN RHEUMATOID ARTHRITIS: A MULTICENTER OBSERVATIONAL STUDY OF 150 PATIENTS

Giacomo Maria Guidelli1, Elena Generali1, Chiara Bazzani2, Roberto Gori3, Garfallia Sakellarious1, Massimiliano Limonta1, Maria Sole Chimenti1, Roberto Perricone1, Edoardo Conti1, Bruno Frediani1, Nicola Boffini1, Lorenzo Dagnan1, Marta Riva1, Maria Rosa Pozzi1, Rossa Daniela Grembiable1, Teodora Serban1, Geralomo Bianchi2, Carlo Selen1,2,3; Humanitas Clinical and Research Center, Rheumatology and Clinical Immunology Unit, Rozzano (MI), Italy; 2Spedali Civili, Rheumatology Unit, Brescia, Italy; 3ASST Papa Giovanni XXIII, Rheumatology Unit, Bergamo, Italy; 4Policlinico Tor Vergata, Rheumatology Unit, Rome, Italy; 5Policlinico Le Scotte, Rheumatology Unit, Siena, Italy; 6IRCCS San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnitAR), Milan, Italy; 7San Gerardo Hospital, Rheumatology Unit, Monza, Italy; 8University “Magna Graecia”, Health Science, Catanzaro, Italy; 9ASL3 Genovese, Division of Rheumatology, Genova, Italy; 10University of Milan, BIOMETRA Department, Milan, Italy

Background: Baricitinib is an oral selective JAK1/2 inhibitor recently approved in the EU for the treatment of rheumatoid arthritis (RA). No real-life data are available about its efficacy and safety.

Objectives: To investigate the efficacy and safety profiles of baricitinib in real-life setting.

Methods: We performed a multicenter prospective observational study on adult RA patients starting JAK inhibitors between 12/2017 and 12/2018. Demographic and clinical data as well as laboratory values and adverse events were collected at baseline and after 12 and 24 weeks. Disease activity was measured by DAS28-3CRP at baseline, after 12 and 24 weeks.

Results: We obtained data from 150 patients with RA (women 116 – 77.3%; median age 60 years, inter-quartile range IQR 54-68; median disease duration 10 years, IQR 4-18) treated with baricitinib 2 or 4 mg OD, however only 2/150 (1.3%) at the reduced dosage. At the time of database lock 95/150 (63%) patients have completed the 2 weeks follow-up, 38/150 (25%) patients have completed the 24 weeks follow-up. Baricitinib was started after at least one conventional synthetic DMARD in all 148/150 cases (99%), being in all cases methotrexate, while was started prior to a biologic DMARD in 57 (38%) patients. It was prescribed as a second line in 179/180 (98%) patients, third in 27 (29%), fourth or higher in 49 (53%). Baricitinib was prescribed as monotherapy in 57/150 (38%) patients, while combined with methotrexate in 65/150 (43%), at a median dosage of 15 mg/week. Oral corticosteroids were used by 105/150 (70%) patients, at a median dosage of 5 mg/day. Mean DAS28-3CRP at baseline was 4.92 (standard deviation 1.22), with 65 (43.3%) patients having a DAS28-3CRP>5.1. At both 12 and 24 weeks, a significant reduction of disease activity scores was observed (DAS28-3CRP mean 3.07, SD 1.36, and 2.85, SD 1.35, respectively; p-values<0.001). Sixteen (11%) patients discontinued the treatment, with 8 (50%) due to primary inefficacy, mainly in the first 3 months of therapy (5/8– 63%). Adverse events were observed in 19/150 (13%) patients, 7 being non-serious infections (4